Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)

Hongyun Huang, Wise Young, Lin Chen, Shiqing Feng, Ziad M.Al Zoubi, Hari Shanker Sharma, Hooshang Saberi, Gustavo A. Moviglia, Xijing He, Dafin F. Muresanu, Alok Sharma, Ali Otom, Russell J. Andrews, Adeeb Al-Zoubi, Andrey S. Bryukhovetskiy, Elena R. Chernykh, Krystyna Domańska-Janik, Emad Jafar, W. Eustace Johnson, Ying LiDaqing Li, Zuo Luan, Gengsheng Mao, Ashok K. Shetty, Dario Siniscalco, Stephen Skaper, Tiansheng Sun, Yunliang Wang, Lars Wiklund, Qun Xue, Si Wei You, Zuncheng Zheng, Milan R. Dimitrijevic, W. S.El Masri, Paul R. Sanberg, Qunyuan Xu, Guoming Luan, Michael Chopp, Kyoung Suok Cho, Xin Fu Zhou, Ping Wu, Kai Liu, Hamid Mobasheri, Seiji Ohtori, Hiroyuki Tanaka, Fabin Han, Yaping Feng, Shaocheng Zhang, Yingjie Lu, Zhicheng Zhang, Yaojian Rao, Zhouping Tang, Haitao Xi, Liang Wu, Shunji Shen, Mengzhou Xue, Guanghong Xiang, Xiaoling Guo, Xiaofeng Yang, Yujun Hao, Yong Hu, Jinfeng Li, Qiang Ao, Bin Wang, Zhiwen Zhang, Ming Lu, Tong Li

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version “Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)”. The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility.

Original languageEnglish (US)
Pages (from-to)310-324
Number of pages15
JournalCell Transplantation
Volume27
Issue number2
DOIs
StatePublished - Feb 1 2018

Keywords

  • cell therapy
  • clinical application guideline neurorestoratology
  • neurorestoration

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Fingerprint Dive into the research topics of 'Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)'. Together they form a unique fingerprint.

  • Cite this

    Huang, H., Young, W., Chen, L., Feng, S., Zoubi, Z. M. A., Sharma, H. S., Saberi, H., Moviglia, G. A., He, X., Muresanu, D. F., Sharma, A., Otom, A., Andrews, R. J., Al-Zoubi, A., Bryukhovetskiy, A. S., Chernykh, E. R., Domańska-Janik, K., Jafar, E., Johnson, W. E., ... Li, T. (2018). Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017). Cell Transplantation, 27(2), 310-324. https://doi.org/10.1177/0963689717746999